According to filings with the U.S. Securities and Exchange Commission, GlycosBio is raising $1,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Richard Cilento played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About GlycosBio
GlycosBio is focused on research and development to improve the delivery and performance of natural bioactive molecules to the body using our plant-based single-solution lipid absorption technologies. Located in the Johnson & Johnson Innovation Center at the Texas Medical Center, we collaborate with scientists and the medical community to design highly functional solutions for diseases where the microbiome is impaired. GlycosBios technologies harness the innate beneficial qualities in plant and marine lipids to provide safe and reliable personalized products. Our mission is to nourish and enhance the lives of people at all stages of life with a focus on fragile populations struggling with microbiome dysbiosis. Using plant-based alternatives our scientists are working to reduce the dependence on antibiotics and prescription medication. Our vision is to modernize and elevate nutrition, skincare, and pulmonary health for all populations from infants to adults using clean technology and clinically driven results.

To learn more about GlycosBio, visit http://www.glycosbio.com/

Contact:
Richard Cilento, Chief Executive Officer
281-643-7234

SOURCE: http://www.intelligence360.io
Copyright (c) 2023 SI360 Inc. All rights reserved.